We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+12.17%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$512M
AUM Growth
+$116M
Cap. Flow
+$65.9M
Cap. Flow %
12.88%
Top 10 Hldgs %
44.62%
Holding
138
New
35
Increased
30
Reduced
28
Closed
26

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$31.8M
2
BIIB icon
Biogen
BIIB
+$21.2M
3
NVS icon
Novartis
NVS
+$19M
4
PFE icon
Pfizer
PFE
+$13M
5
CELG
Celgene Corp
CELG
+$8.38M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$13.8M
2
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$13M
3
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$11.9M
4
MRK icon
Merck
MRK
+$9.86M
5
AKAO
Achaogen Inc
AKAO
+$6.46M

Sector Composition

Rank Sector Weight
1 Healthcare 64.14%
2 Miscellaneous 24.59%
3 Technology 4.38%
4 Communication Services 1.99%
5 Industrials 1.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLB icon
51
SLB Ltd
SLB
$77.3B
$2.73M 0.53%
34,911
+550
+2% +$45K
SBUX icon
52
Starbucks
SBUX
$110B
$2.72M 0.53%
46,631
+1,000
+2% +$56.6K
PRTK
53
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$2.69M 0.53%
140,000
– –
SNA icon
54
Snap-on
SNA
$19.2B
$2.66M 0.52%
15,797
+4,825
+44% +$830K
XLRN
55
DELISTED
Acceleron Pharma
XLRN
$2.65M 0.52%
100,000
– –
PVLA
56
Palvella Therapeutics
PVLA
$2.22B
$2.6M 0.51%
12,500
+2,375
+23% +$420K
CTMX icon
57
CytomX Therapeutics
CTMX
$614M
$2.59M 0.51%
+150,000
New +$1.97M
META icon
58
Meta Platforms (Facebook)
META
$1.74T
$2.57M 0.5%
18,092
+5,030
+39% +$672K
STML
59
DELISTED
Stemline Therapeutics, Inc.
STML
$2.56M 0.5%
+300,000
New +$2.73M
BLCM
60
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$2.47M 0.48%
+20,000
New +$2.62M
CASC
61
DELISTED
Cascadian Therapeutics, Inc.
CASC
$2.41M 0.47%
+581,210
New +$2.44M
CLSD
62
DELISTED
Clearside Biomedical
CLSD
$2.38M 0.47%
20,000
– –
MRNS
63
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$2.36M 0.46%
332,855
-2,292
-0.7% -$12.3K
FWP
64
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$2.33M 0.46%
15,432
-1,925
-11% -$363K
SNDX icon
65
Syndax Pharmaceuticals
SNDX
$1.58B
$2.28M 0.45%
166,310
– –
SGEN
66
DELISTED
Seagen Inc. Common Stock
SGEN
$2.26M 0.44%
+36,000
New +$2.25M
OBSV
67
DELISTED
ObsEva SA Ordinary Shares
OBSV
$2.2M 0.43%
+211,086
New +$2.59M
TBT icon
68
ProShares Trust UltraShort Lehman 20+ Year Treasury
TBT
$308M
$2.19M 0.43%
55,950
+37,300
+200% +$1.49M
ZYNE
69
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$2.01M 0.39%
+100,000
New +$1.99M
SMMT icon
70
Summit Therapeutics
SMMT
$14.1B
$1.97M 0.38%
147,450
– –
VTVT icon
71
vTv Therapeutics
VTVT
$124M
$1.97M 0.38%
7,500
+2,500
+50% +$570K
CYTK icon
72
Cytokinetics
CYTK
$9.72B
$1.96M 0.38%
+152,200
New +$1.78M
SPNS
73
DELISTED
Sapiens International
SPNS
$1.9M 0.37%
147,306
+37,984
+35% +$525K
TJX icon
74
TJX Companies
TJX
$139B
$1.79M 0.35%
+45,400
New +$1.75M
AVEO
75
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$1.71M 0.33%
+290,000
New +$2.09M
1 2
3
4 5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q1 2017 Portfolio in Review

As of Q1 2017, Sphera Funds Management held 138 positions worth $512M, up 29% from $395M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management deployed $65.9M of net new capital in Q1 2017, opening 35 new positions and adding to 30 existing holdings. Its largest new stake was Biogen: 75,000 shares worth $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 67% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Teva Pharmaceutical Industries Limited, an estimated $11.9M trimmed.

  • Sphera Funds Management's largest Q1 2017 buy was Biogen: 75,000 shares worth $20.5M.
  • Sphera Funds Management added most to Shire pic in Q1 2017, an estimated $31.8M increase.
  • Sphera Funds Management's biggest Q1 2017 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $11.9M.
  • Sphera Funds Management fully exited Alexion Pharmaceuticals in Q1 2017, selling an estimated $13.8M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $512M portfolio in Q1 2017.
  • Sphera Funds Management opened 35 new positions and closed 26 in Q1 2017.
  • Sphera Funds Management's portfolio value rose 29% quarter-over-quarter to $512M.

Based on Sphera Funds Management's 13F filing for Q1 2017, filed 11 May 2017.